|
Living Medical Textbook From Projects In Knowledge |
|
| Chapter 1 Immunology in Review Last Updated: August 07, 2009 |
||
| Chapter 2 Tumor-Fighting T-Cells Last Updated: September 22, 2009 |
||
| Chapter 3 Costimulation and the T-Cell Response Last Updated: October 01, 2009 |
||
| Chapter 4 Targeting Immune Stimulation: Clinical Application of Immunology Last Updated: October 31, 2009 |
||
| Chapter 5 Autoimmune Effects of CTLA-4 Antibodies: Management and Correlation with Benefit Last Updated: November 18, 2009 |
||
|
|
||||||||||||||||
| Chapter 3 – Costimulation and the T-Cell Response | ||||||||||||||||
|
||||||||||||||||
|
Activity Goal The goal of this CME activity is to examine the role of the immune system in fighting cancer and potential strategies for re-educating the immune system to break tolerance of "self" antigens that mask tumors from cellular immunity. |
||||||||||||||||
|
Target Audience This activity is designed for medical oncologists, dermatologists, and other clinicians who interact with patients with melanoma or other solid tumors. |
||||||||||||||||
Learning Objective
|
||||||||||||||||
| top |
||||||||||||||||
|
CME Information: Physicians
Statement of Accreditation Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Projects In Knowledge designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. top |
||||||||||||||||
|
Disclosure Information The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR). Jeffrey S. Weber, MD, PhD, has mutual patent ownership of ipilimumab with Bristol-Myers Squibb and Medarex, Inc. F. Stephen Hodi, MD, has received grant/research support from Bristol-Myers Squibb, Medarex, Inc, Novartis Pharmaceuticals Corporation, and Pfizer, Inc; is a consultant for Bristol-Myers Squibb; and is on the advisory board for Novartis Pharmaceuticals Corporation. Lauren A. Cerruto has no significant relationships to disclose. Peer Reviewer has disclosed no significant relationships. Projects In Knowledge’s staff members have no significant relationships to disclose. top |
||||||||||||||||
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process. The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge. This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|
||||||||||||||||
|
||||||||||||||||
|
|
|
|
|
This independent CME activity is supported by educational grants from
Bristol-Myers Squibb
Pfizer Inc |
|
|
Release Date: October 1, 2008. Termination Date: October 1, 2009. |
|
Estimated time for completion of this activity: 2.0 hours |
|
CME Instructions To obtain CME credit for this activity:
There is no fee for this activity. |
|
